Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Int J Drug Policy. 2020 Mar 9;88:102710. doi: 10.1016/j.drugpo.2020.102710

Figure 2. Annual DAA treatment numbers (B) required (with or without combination scale-up) to achieve an 80% incidence reduction among PWID by 2030 in Tijuana, Mexico, if treatment is prioritized to current PWID or allocated to current and former PWID. Scenarios examine combination scale-up of DAAs with evidence-based harm reduction (OAT+HCNSP) or involuntary exposure to compulsory drug abstinence programs (CAP).

Figure 2.

DAAs: HCV direct-acting antiviral treatment; OAT: Opiate agonist therapy; HCNSP: High coverage needle/syringe exchange program (receiving ≥1 sterile syringes per injection).